natriumklorid braun cum glucos 9 mg/ml + 50 mg/ml infuusioneste, liuos
b. braun melsungen ag - glucose monohydrate, sodium chloride - infuusioneste, liuos - 9 mg/ml + 50 mg/ml - elektrolyytit ja hiilihydraatit
naloxon b. braun 0.4 mg/ml injektio-/infuusioneste, liuos
b. braun melsungen ag - naloxone hydrochloride dihydrate - injektio-/infuusioneste, liuos - 0.4 mg/ml - naloksoni
nutriflex omega special infuusioneste, emulsio
b. braun melsungen ag - serinum,natrii chloridum,tryptophanum,phenylalaninum,histapyrrodini hydrochloridum,acidum aminoaceticum,magnesii acetas tetrahydricum,calcii chloridum dihydricum,zinci acetas dihydricus,lysini hydrochloridum,soiae oleum raffinatum,threoninum,alaninum,omega-3 acidorum triglycerida,argininum,isoleucinum,kalii acetas,acidum glutamicum,valinum,natrii dihydrogenophosphas dihydricus,leucinum,prolinum,glucosum monohydricum,triglyserida mediocatenalia,natrii acetas trihydricus,natrii hydroxidum - infuusioneste, emulsio - yhdistelmävalmisteet
kaliumklorid braun 150 mg/ml infuusiokonsentraatti, liuosta varten
b. braun melsungen ag - potassium chloride - infuusiokonsentraatti, liuosta varten - 150 mg/ml - kaliumkloridi
ondansetron b. braun 2 mg/ml injektioneste, liuos
b. braun melsungen ag - ondansetron hydrochloride dihydrate - injektioneste, liuos - 2 mg/ml - ondansetroni
ondansetron b. braun 0.08 mg/ml infuusioneste, liuos
b. braun melsungen ag - ondansetron hydrochloride dihydrate - infuusioneste, liuos - 0.08 mg/ml - ondansetroni
ondansetron b. braun 0.16 mg/ml infuusioneste, liuos
b. braun melsungen ag - ondansetron hydrochloride dihydrate - infuusioneste, liuos - 0.16 mg/ml - ondansetroni
dexmedetomidine b. braun 100 mikrog/ml infuusiokonsentraatti, liuosta varten
b. braun melsungen ag - dexmedetomidine hydrochloride - infuusiokonsentraatti, liuosta varten - 100 mikrog/ml - deksmedetomidiini
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).